Celldex Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Celldex Therapeutics Inc.
- Former names
- Avant Immunotherapeutics Inc T Cell Sciences Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2835 — In Vitro & In Vivo Diagnostic Substances
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Hampton
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CLDX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000744218
- EIN
- 13-3191702
Board of directors
-
Anthony S. Marucci · Director · PRESIDENT & CEOSince 2023
-
Cheryl Cohen · DirectorSince 2023
-
Denice Torres · DirectorSince 2025
-
Garry Arthur Neil · DirectorSince 2023
-
Harry Penner Jr. · DirectorSince 2023
-
Herbert J. Conrad · DirectorSince 2023
-
James J. Marino · DirectorSince 2023
-
Karen L. Shoos · DirectorSince 2023
-
Keith L. Brownlie · DirectorSince 2023
- Since 2023
Chief executives
Anthony S. Marucci
· PRESIDENT & CEO
Dates unknown
Director election results
Annual meeting of June 25, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
98.4%
-
98.4%
-
98.5%
-
98.9%
-
99.0%
-
99.3%
-
99.4%
Board connections
6 of this board's directors also sit on 10 other boards.
- via Garry Arthur Neil and Rita Jain
- via Rita Jain
- via Rita Jain
- via Denice Torres
- via Cheryl Cohen
- via Herbert J. Conrad
- via Rita Jain
- via Denice Torres
- via James J. Marino
- via Garry Arthur Neil
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,304,383
- 2 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 2, 2026 | Martin Samuel Bates Officer (SVP AND CFO) | Option exercise | +4,817 | $10.38 | $50,000 |
| Dec 15, 2025 | PEPIN RONALD Officer (SR. VP & CBO) | Option exercise | +8,333 | $9.02 | $75,164 |
| Dec 15, 2025 | PEPIN RONALD Officer (SR. VP & CBO) | Option exercise | +11,000 | $2.78 | $30,580 |
| Dec 4, 2025 | Jimenez Freddy A. Officer (SVP & GENERAL COUNSEL) | Open-market sale | −4,166 | $29.10 | $121,231 |
| Nov 13, 2025 | Wright Richard M. Former Officer | Option exercise | +6,876 | $9.02 | $62,022 |
| Nov 13, 2025 | Wright Richard M. Former Officer | Option exercise | +26,672 | $10.38 | $276,855 |
| Nov 13, 2025 | Wright Richard M. Former Officer | Option exercise | +15,750 | $22.48 | $354,060 |
| Nov 13, 2025 | Wright Richard M. Former Officer | Open-market sale | −49,298 | $24.00 | $1,183,152 |
| Aug 13, 2025 | Jimenez Freddy A. Officer (SVP & GENERAL COUNSEL) | Open-market sale | −341 | $23.95 | $8,167 |
| Aug 13, 2025 | Jimenez Freddy A. Officer (SVP & GENERAL COUNSEL) | Open-market sale | −430 | $25.42 | $10,931 |
| Nov 18, 2024 | James J. Marino Director | Gift | −10,500 | — | — |
| Nov 11, 2024 | Anthony S. Marucci Director, Officer (PRESIDENT & CEO) | Open-market purchase | +11,500 | $26.82 | $308,430 |
| Jun 14, 2024 | Martin Samuel Bates Officer (SVP AND CFO) | Option exercise | +3,201 | $9.02 | $28,873 |
| Jun 14, 2024 | Crowley Elizabeth Officer (SR. VP & CPDO) | Option exercise | +30,000 | $10.38 | $311,400 |
| Jun 14, 2024 | Martin Samuel Bates Officer (SVP AND CFO) | Option exercise | +16,968 | $10.38 | $176,128 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.